These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 21224449)

  • 1. CETP inhibition shows promise as way to reduce cardiovascular disease risk.
    Mitka M
    JAMA; 2011 Jan; 305(2):136-7. PubMed ID: 21224449
    [No Abstract]   [Full Text] [Related]  

  • 2. CETP inhibition, statins and diabetes.
    Barter PJ; Cochran BJ; Rye KA
    Atherosclerosis; 2018 Nov; 278():143-146. PubMed ID: 30278356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [HDL and CETP in atherogenesis].
    Pöss J; Böhm M; Laufs U
    Dtsch Med Wochenschr; 2010 Feb; 135(5):188-92. PubMed ID: 20082258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Researchers still seek clinical benefit in raising levels of good cholesterol.
    Mitka M
    JAMA; 2012 Jan; 307(1):21-2. PubMed ID: 22215155
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial.
    Brinton EA; Kher U; Shah S; Cannon CP; Davidson M; Gotto AM; Ashraf TB; McCrary Sisk C; Dansky H; Mitchel Y; Barter P;
    J Clin Lipidol; 2015; 9(1):65-71. PubMed ID: 25670362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is Anacetrapib Better Than Its CETP Inhibitor Counterparts?
    Grabie M; Tai CH; Frishman WH
    Cardiol Rev; 2019; 27(5):242-248. PubMed ID: 30601160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Future of cholesteryl ester transfer protein inhibitors.
    Rader DJ; deGoma EM
    Annu Rev Med; 2014; 65():385-403. PubMed ID: 24422575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Secondary coronary heart disease prevention. Will CEPT inhibitors be the next breakthrough?].
    Einecke D
    MMW Fortschr Med; 2011 Dec; 153(49-50):17-8. PubMed ID: 22308584
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of HDL-modifiers on cardiovascular outcomes: a meta-analysis of randomized trials.
    Verdoia M; Schaffer A; Suryapranata H; De Luca G
    Nutr Metab Cardiovasc Dis; 2015 Jan; 25(1):9-23. PubMed ID: 25439661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Statin cuts cardiovascular risk in half].
    Einecke D
    MMW Fortschr Med; 2008 Dec; 150(49-50):12-3. PubMed ID: 19133364
    [No Abstract]   [Full Text] [Related]  

  • 11. Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis.
    Masson D
    Curr Opin Investig Drugs; 2009 Sep; 10(9):980-7. PubMed ID: 19705341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now?
    Barter P; Rye KA
    Trends Pharmacol Sci; 2011 Dec; 32(12):694-9. PubMed ID: 22088767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRP: star trekking the galaxy of risk markers.
    Després JP
    Lancet; 2011 Feb; 377(9764):441-2. PubMed ID: 21277015
    [No Abstract]   [Full Text] [Related]  

  • 14. Anacetrapib, a cholesteryl ester transfer protein inhibitor.
    Hooper AJ; Burnett JR
    Expert Opin Investig Drugs; 2012 Jan; 21(1):103-9. PubMed ID: 22191425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on the discovery and development of cholesteryl ester transfer protein inhibitors for reducing residual cardiovascular risk.
    Mantlo NB; Escribano A
    J Med Chem; 2014 Jan; 57(1):1-17. PubMed ID: 23941686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reduction.
    Gutstein DE; Krishna R; Johns D; Surks HK; Dansky HM; Shah S; Mitchel YB; Arena J; Wagner JA
    Clin Pharmacol Ther; 2012 Jan; 91(1):109-22. PubMed ID: 22130116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Good news for 'good' cholesterol.
    Katsnelson A
    Nature; 2010 Nov; 468(7322):354. PubMed ID: 21085143
    [No Abstract]   [Full Text] [Related]  

  • 18. Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? CETP Inhibition as a Strategy to Reduce Cardiovascular Risk: The Pro Case.
    Barter PJ; Nicholls SJ; Kastelein JJ; Rye KA
    Circulation; 2015 Aug; 132(5):423-32. PubMed ID: 26240263
    [No Abstract]   [Full Text] [Related]  

  • 19. On-statin cholesteryl ester transfer protein mass and risk of recurrent coronary events (from the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 [PROVE IT-TIMI 22] study).
    Khera AV; Wolfe ML; Cannon CP; Qin J; Rader DJ
    Am J Cardiol; 2010 Aug; 106(4):451-6. PubMed ID: 20691300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The numbers are in: statins for the primary prevention of cardiovascular disease in women.
    Duvernoy CS; Blumenthal R
    Circulation; 2010 Mar; 121(9):1063-5. PubMed ID: 20176993
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.